Market Research Report
Proto Oncogene Tyrosine Protein Kinase Src - Drugs In Development, 2021
|Proto Oncogene Tyrosine Protein Kinase Src - Drugs In Development, 2021|
Published: June 30, 2021
Global Markets Direct
Content info: 109 Pages
Delivery time: 1-2 business days
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 220.127.116.11) pipeline Target constitutes close to 20 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Proto Oncogene Tyrosine Protein Kinase Src - Drugs In Development, 2021, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 18.104.22.168) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 22.214.171.124) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. The molecules developed by companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 3, 7, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Respiratory, Central Nervous System, Gastrointestinal, Genetic Disorders, Infectious Disease, Musculoskeletal Disorders and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Colorectal Cancer, Idiopathic Pulmonary Fibrosis, Ulcerative Colitis, Central Nervous System (CNS) Tumor, Endometrial Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Interstitial Lung Fibrosis, Lymphangioleiomyomatosis, Medullary Thyroid Cancer, Melanoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alcohol Addiction, Anaplastic Large Cell Lymphoma (ALCL), Angiosarcoma, Bladder Cancer, Breast Cancer, Brenner Tumor, Bronchiolitis Obliterans, Cervical Cancer, Coronavirus Disease 2019 (COVID-19) Pneumonia, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Friedreich Ataxia, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease), Keratoconjunctivitis Sicca (Dry Eye), Lewy Body Dementia, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Malignant Pleural Mesothelioma, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pancreatic Cancer, Papillary Thyroid Cancer, Parkinson's Disease, Peritoneal Cancer, Pneumoconiosis, Psychosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Salivary Gland Cancer, Squamous Non-Small Cell Lung Cancer, Thyroid Cancer, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Uterine Cancer.
Furthermore, this report also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 126.96.36.199) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.